Literature DB >> 26920405

Long-Term Follow-Up of Patients Undergoing Resection of TNM Stage I Colorectal Cancer: An Analysis of Tumour and Host Determinants of Outcome.

David Mansouri1, Arfon G Powell2,3, James H Park2, Donald C McMillan2, Paul G Horgan2.   

Abstract

BACKGROUND: Screening for colorectal cancer improves cancer-specific survival (CSS) through the detection of early-stage disease; however, its impact on overall survival (OS) is unclear. The present study examined tumour and host determinants of outcome in TNM Stage I disease.
METHODS: All patients with pathologically confirmed TNM Stage I disease across 4 hospitals in the North of Glasgow between 2000 and 2008 were included. The preoperative modified Glasgow Prognostic Score (mGPS) was used as a marker of the host systemic inflammatory response (SIR).
RESULTS: There were 191 patients identified, 105 (55 %) were males, 91 (48 %) were over the age of 75 years and 7 (4 %) patients underwent an emergency operation. In those with a preoperative CRP result (n = 150), 35 (24 %) patients had evidence of an elevated mGPS. Median follow-up of survivors was 116 months (minimum 72 months) during which 88 (46 %) patients died; 7 (8 %) had postoperative deaths, 15 (17 %) had cancer-related deaths and 66 (75 %) had non-cancer-related deaths. 5-year CSS was 95 % and OS was 76 %. On univariate analysis, advancing age (p < 0.001), emergency presentation (p = 0.008), and an elevated mGPS (p = 0.012) were associated with reduced OS. On multivariate analysis, only age (HR = 3.611, 95 % CI 2.049-6.365, p < 0.001) and the presence of an elevated mGPS (HR = 2.173, 95 % CI 1.204-3.921, p = 0.010) retained significance.
CONCLUSIONS: In patients undergoing resection for TNM Stage I colorectal cancer, an elevated mGPS was an objective independent marker of poorer OS. These patients may benefit from a targeted intervention.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26920405     DOI: 10.1007/s00268-016-3443-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  47 in total

Review 1.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

Review 3.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

4.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

5.  The potential for prevention of colorectal cancer in the UK.

Authors:  Donald Maxwell Parkin; Anne-Helene Olsen; Peter Sasieni
Journal:  Eur J Cancer Prev       Date:  2009-06       Impact factor: 2.497

6.  The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer.

Authors:  C H Richards; E F Leitch; P G Horgan; J H Anderson; R F McKee; D C McMillan
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

7.  Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95).

Authors:  Margit Fröhlich; Malte Sund; Hannelore Löwel; Armin Imhof; Albrecht Hoffmeister; Wolfgang Koenig
Journal:  Eur Heart J       Date:  2003-07       Impact factor: 29.983

8.  The clinical utility of the combination of T stage and venous invasion to predict survival in patients undergoing surgery for colorectal cancer.

Authors:  Campbell S D Roxburgh; Donald C McMillan; Colin H Richards; Manal Atwan; John H Anderson; Tim Harvey; Paul G Horgan; Alan K Foulis
Journal:  Ann Surg       Date:  2014-06       Impact factor: 12.969

Review 9.  Cancer-related inflammation and treatment effectiveness.

Authors:  Connie I Diakos; Kellie A Charles; Donald C McMillan; Stephen J Clarke
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

10.  Systemic inflammation predicts all-cause mortality: a glasgow inflammation outcome study.

Authors:  Michael J Proctor; Donald C McMillan; Paul G Horgan; Colin D Fletcher; Dinesh Talwar; David S Morrison
Journal:  PLoS One       Date:  2015-03-02       Impact factor: 3.240

View more
  3 in total

1.  Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients.

Authors:  Yongbin Lv; Yinghua Pan; Changxia Dong; Peiji Liu; Chunping Zhang; Dong Xing
Journal:  Med Sci Monit       Date:  2017-08-04

2.  Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.

Authors:  Xiaobing Wang; Zhaogang Yang; Haimei Tian; Yanfen Li; Mo Li; Wenya Zhao; Chao Zhang; Teng Wang; Jing Liu; Aili Zhang; Di Shen; Cuining Zheng; Jun Qi; Dan Zhao; Junfeng Shi; Liliang Jin; Jianyu Rao; Wei Zhang
Journal:  Oncotarget       Date:  2017-04-11

3.  Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer.

Authors:  Renate S Olsen; Johnny Nijm; Roland E Andersson; Jan Dimberg; Dick Wågsäter
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.